Browsing by Author "Alm, Erik"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- Emergence of ST131 carrying carbapenemase genes, European Union/European Economic Area, August 2012 to May 2024Publication . Kohlenberg, Anke; Svartström, Olov; Apfalter, Petra; Hartl, Rainer; Bogaerts, Pierre; Huang, Te-Din; Chudejova, Katerina; Malisova, Lucia; Eisfeld, Jessica; Sandfort, Mirco; Hammerum, Anette M.; Roer, Louise; Räisänen, Kati; Dortet, Laurent; Bonnin, Rémy A.; Tóth, Ákos; Tóth, Kinga; Clarke, Christina; Cormican, Martin; Griškevičius, Algirdas; Khonyongwa, Kirstin; Meo, Marie; Niedre-Otomere, Baiba; Vangravs, Reinis; Hendrickx, Antoni Pa; Notermans, Daan W; Samuelsen, Ørjan; Caniça, Manuela; Manageiro, Vera; Müller, Vilhelm; Mäkitalo, Barbro; Kramar, Urška; Pirs, Mateja; Palm, Daniel; Monnet, Dominique L.; Alm, Erik; Linkevicius, MariusAnalysis of 594 isolates of sequence type (ST)131 and its single locus variants carrying carbapenemase genes from 17 European Union/European Economic Area countries revealed acquisition of 18 carbapenemase variants, mainly in ST131 clades A and C. Most frequent were (n = 230) and (n = 224), detected in 14 and 12 countries, respectively. Isolates carrying have increased rapidly since 2021. The increasing detection of carbapenemase genes in the high-risk lineage ST131 is a public health concern.
- Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020Publication . Alm, Erik; Broberg, Eeva K; Connor, Thomas; Hodcroft, Emma B; Komissarov, Andrey B; Maurer-Stroh, Sebastian; Melidou, Angeliki; Neher, Richard A; O’Toole, Áine; Pereyaslov, Dmitriy; WHO European Region sequencing laboratories and GISAID EpiCoV group; WHO European Region sequencing laboratories and GISAID EpiCoV groupWe show the distribution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic clades over time and between countries and outline potential genomic surveillance objectives. We applied three genomic nomenclature systems to all sequence data from the World Health Organization European Region available until 10 July 2020. We highlight the importance of real-time sequencing and data dissemination in a pandemic situation, compare the nomenclatures and lay a foundation for future European genomic surveillance of SARS-CoV-2.
- Rapid cross-border emergence of NDM-5-producing Escherichia coli in the European Union/European Economic Area, 2012 to June 2022Publication . Linkevicius, Marius; Bonnin, Rémy A.; Alm, Erik; Svartström, Olov; Apfalter, Petra; Hartl, Rainer; Hasman, Henrik; Roer, Louise; Räisänen, Kati; Dortet, Laurent; Pfennigwerth, Niels; Hans, Jörg B.; Tóth, Ákos; Buzgó, Lilla; Cormican, Martin; Delappe, Niall; Monaco, Monica; Giufrè, Maria; Hendrickx, Antoni P.A.; Samuelsen, Ørjan; Pöntinen, Anna K.; Caniça, Manuela; Manageiro, Vera; Oteo-Iglesias, Jesús; Pérez-Vázquez, María; Westmo, Karin; Mäkitalo, Barbro; Palm, Daniel; Monnet, Dominique L.; Kohlenberg, AnkeWhole genome sequencing data of 874 Escherichia coli isolates carrying bla NDM-5 from 13 European Union/European Economic Area countries between 2012 and June 2022 showed the predominance of sequence types ST167, ST405, ST410, ST361 and ST648, and an increasing frequency of detection. Nearly a third (30.6%) of these isolates were associated with infections and more than half (58.2%) were predicted to be multidrug-resistant. Further spread of E. coli carrying bla NDM-5 would leave limited treatment options for serious E. coli infections.